Who are BridgeBio Pharma, Inc.'s main suppliers?

BridgeBio Pharma, Inc. (BBIO) key suppliers include: GOLDMAN-SACHS-CO-LLC, LEERINK-PARTNERS-LLC, BridgeBio Oncology Therapeutics, Inc., RVMDW, Septerna, Inc.. View the full supplier network at chainsifter.com/chain/BBIO.

Who are BridgeBio Pharma, Inc.'s major customers?

BridgeBio Pharma, Inc. (BBIO) key customers include: BAYER, BridgeBio Oncology Therapeutics, Inc., BridgeBio Oncology Therapeutics, Inc., KKR & Co. Inc., KKR & Co. Inc. and 13 more. View the full customer network at chainsifter.com/chain/BBIO.

What sector is BridgeBio Pharma, Inc. in?

BridgeBio Pharma, Inc. (BBIO) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

BridgeBio Pharma, Inc. Suppliers, Customers & Supply Chain (BBIO)

5Suppliers

18Customers

3Debt Items

20Related Chains

Source-Backed Evidence Depth

BridgeBio Pharma, Inc. (BBIO) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

27Total relationships

3Distinct source URLs

7High confidence

0.730Average confidence

2026-10-28Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

BridgeBio Pharma, Inc. Suppliers

Ticker	Name	Confidence	Evidence
GOLDMAN-SACHS-CO-LLC	GOLDMAN-SACHS-CO-LLC	90%	the Company entered into an Equity Distribution Agreement (the “Agreement”) with Goldman Sachs & Co. LLC
LEERINK-PARTNERS-LLC	LEERINK-PARTNERS-LLC	90%	the Company entered into an Equity Distribution Agreement (the “Agreement”) with Goldman Sachs & Co. LLC and Leerink Partners LLC
BBOT	BridgeBio Oncology Therapeutics, Inc.	72%	Reciprocal relationship from BBOT graph: Reciprocal relationship from BBIO graph: Reciprocal relationship from BBOT graph: Reciprocal relationship from BBIO graph: Reciprocal relationship from BBOT g…
RVMDW	RVMDW	72%	Reciprocal relationship from RVMDW graph: the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated revenu…
SEPN	Septerna, Inc.	72%	Reciprocal relationship from SEPN graph: result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated prob…

BridgeBio Pharma, Inc. Customers

Ticker	Name	Confidence	Evidence
BAYER	BAYER	90%	Three Months Ended March 31, 2026 2025 Bayer (as described in Note 10) * 59.6 %
BBOT	BridgeBio Oncology Therapeutics, Inc.	72%	Reciprocal relationship from BBOT graph: Reciprocal relationship from BBIO graph: quity financing with external investors to accelerate the development of its oncology portfolio. Upon completion of t…
BBOT	BridgeBio Oncology Therapeutics, Inc.	72%	quity financing with external investors to accelerate the development of its oncology portfolio. Upon completion of the private equity financing, the Company’s ownership of Legacy BBOT’s equity was r…
KKR	KKR & Co. Inc.	72%	Reciprocal relationship from KKR graph: Reciprocal relationship from BBIO graph: oing developments in connection with economic conditions, inflationary pressures, evolving regulatory and policy lands…
KKR	KKR & Co. Inc.	72%	oing developments in connection with economic conditions, inflationary pressures, evolving regulatory and policy landscapes, supply chain issues, our commercialization of Attruby/Beyonttra, and timin…
OBDC	Blue Owl Capital Corporation	72%	Item 1A for further discussion related to our royalty monetization arrangements. The conditional conversion feature of the Notes, if triggered, may adversely affect our financial condition and operat…
OBDC	Blue Owl Capital Corporation	72%	Reciprocal relationship from OBDC graph: Reciprocal relationship from BBIO graph: Reciprocal relationship from OBDC graph: Reciprocal relationship from BBIO graph: Reciprocal relationship from OBDC g…
RVMDW	RVMDW	72%	Reciprocal relationship from RVMDW graph: Reciprocal relationship from BBIO graph: Reciprocal relationship from RVMDW graph: Reciprocal relationship from BBIO graph: Reciprocal relationship from RVMD…
ALEXION-PHARMACEUTICALS-INC	ALEXION-PHARMACEUTICALS-INC	62%	nt payment of $ 100.0 million and development and sales milestone payments up to $ 81.4 million. To date, we have received $ 100.0 million relating to the upfront payment. In addition, QED is entitle…
ALEXION-PHARMA-INTERNATIONAL-OPERATIONS-LIMITED-	ALEXION-PHARMA-INTERNATIONAL-OPERATIONS-LIMITED-	62%	nt payment of $ 100.0 million and development and sales milestone payments up to $ 81.4 million. To date, we have received $ 100.0 million relating to the upfront payment. In addition, QED is entitle…
A-R-LLC	A-R-LLC	62%	, the FASB issued ASU 2025-06, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software . This ASU makes targeted …
BAYER-AG	BAYER-AG	62%	(including the Buy-Out Payment and all reimbursable expenses). The Funding Agreement will also terminate upon customary events. Under the Funding Agreement, the Seller Parties are required to comply …
BAYER-CONSUMER-CARE-AG	BAYER-CONSUMER-CARE-AG	62%	(including the Buy-Out Payment and all reimbursable expenses). The Funding Agreement will also terminate upon customary events. Under the Funding Agreement, the Seller Parties are required to comply …
EIDOS-BRIDGEBIO-INTERNATIONAL-GMBH	EIDOS-BRIDGEBIO-INTERNATIONAL-GMBH	62%	oing developments in connection with economic conditions, inflationary pressures, evolving regulatory and policy landscapes, supply chain issues, our commercialization of Attruby/Beyonttra, and timin…
GONDOLABIO-LLC	GONDOLABIO-LLC	62%	, the FASB issued ASU 2025-06, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software . This ASU makes targeted …
KYOWA-KIRIN-CO-LTD	KYOWA-KIRIN-CO-LTD	62%	ructure starting in the low-thirties percent on net sales by Bayer of acoramidis in the Licensed Territory, subject to reduction under certain circumstances as provided in the Bayer License Agreement…
NVTS	Navitas Semiconductor Corporation	62%	Reciprocal relationship from NVTS graph: Reciprocal relationship from BBIO graph: Reciprocal relationship from NVTS graph: Reciprocal relationship from BBIO graph: Reciprocal relationship from NVTS g…
PORTAL-THERAPEUTICS-INC	PORTAL-THERAPEUTICS-INC	62%	, the FASB issued ASU 2025-06, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software . This ASU makes targeted …

BridgeBio Pharma, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
BBIO-DEBT-8076	Warrants outstanding: -984000	90%	xbrl warrant detail from xbrl 2023-12-31.
BBIO-DEBT-8077	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2023-12-31.
BBIO-DEBT	Debt stack $3.6M	90%	Market cache reports total debt of $3.6M.

BridgeBio Pharma, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for BridgeBio Pharma, Inc..

BridgeBio Pharma, Inc. Ownership

Holder	Name	Confidence	Evidence
BBIO-OWNER-JANUS-HENDERSON-GROUP-PLC	JANUS HENDERSON GROUP PLC	90%	13F overlay lists JANUS HENDERSON GROUP PLC as top holder; 466 tracked holders.

BridgeBio Pharma, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
SEPN	Septerna, Inc.	100.00	1	['supplier']
OTF	Blue Owl Technology Finance Corp.	100.00	2
KKR	KKR & Co. Inc.	100.00	1	['customer']
RVMDW	Revolution Medicines, Inc.	100.00	1	['customer', 'supplier']
MBX	MBX Biosciences, Inc.	100.00	2
OBDC	Blue Owl Capital Corporation	100.00	1	['customer']
CLDX	Celldex Therapeutics, Inc.	100.00	2
JSPR	Jasper Therapeutics, Inc.	100.00	2
KREF	KKR Real Estate Finance Trust Inc.	100.00	2
MDGL	Madrigal Pharmaceuticals, Inc.	100.00	2
TERN	Terns Pharmaceuticals, Inc.	100.00	2
LLY	Eli Lilly and Company	100.00	2
BBOT	BridgeBio Oncology Therapeutics, Inc.	100.00	1	['customer', 'supplier']
NVTS	Navitas Semiconductor Corporation	100.00	1	['customer']
GPCR	Structure Therapeutics Inc.	100.00	2
DB	Deutsche Bank Aktiengesellschaft	100.00	2
EYE	National Vision Holdings, Inc.	100.00	2
TGTX	TG Therapeutics, Inc.	100.00	2
ANL	Adlai Nortye Ltd.	100.00	2
PAR	PAR Technology Corporation	100.00	2

BridgeBio Pharma, Inc. Supply Chain